Skip to Main Content

Paper Details

Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.
JACC Heart Fail
1
2023
C-reactive protein, CVD, HF, Heart Failure, N, N-terminal pro-B-type natriuretic peptide, Patient, Patients, Vericiguat, cardiac troponin T, cardiovascular death, cystatin C, growth differentiation factor 15, heart failure, high-sensitivity, high-sensitivity C-reactive protein, hypotension, interleukin 6, patients, syncope, vericiguat
Author NameAffiliation
Christopher R deFilippiInova Heart and Vascular Institute
Adrian F HernandezDuke Clinical Research Institute, Duke University School of Medicine
Carolyn S P LamNational Heart Centre Singapore and Duke-National University of Singapore
  • 1 - 3

Datasets

Release 1.2